Evaluation of efficacy, safety and tolerability...

In the News

Study establishes link between gender, extramarital affairs and HIV

Dar es Salaam. A new Ifakara Health Institute study has found “a significant association between lifetime (proxy) extramarital affairs and HIV infection among women only,” with the risk being significantly …

IHI names winners of research, innovation fund

[Right-Left] Getrud, Beatrice, Theckla, and Tutu.Ifakara Health Institute (IHI) has named recipients of the 2017/18 Director’s Research and Innovation Fund. This is an internal funding mechanism aimed to support specific …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

A Phase 3 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA‐824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug‐Sensitive Smear‐Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi‐Drug Resistant, Smear‐Positive Pulmonary Tuberculosis (STAND Trial).

The STAND trial, sponsored by the Global Alliance for TB Drug Development (TB Alliance) is a multi-center and multi-country study with over 50 study sites across Africa, Asia, Eastern Europe and Latin America. The trial is on the new three-drug regimen PaMZ for both TB and MDR-TB patients. In Tanzania the study is done in four sites: IHI (PI, Dr. Francis Mhimbira), Mbeya Medical Research Center-NIMR (PI, Dr. Issa Sabi), Kilimanjaro Clinical Research Institute (KCRI)-Moshi (Prof. Blandina Mmbaga) and NIMR-Mwanza (PI, Dr. George Praygod). The STAND trial is expected to run for 4 years. It is a Phase 3 Open‐Label Partially Randomized Trial.

Lead Scientists:

Francis Mhimbira

Frederick Haraka

Partners

National Institute of Medical Research
Kilimanjaro Clinical Research Institute
TB Alliance

Funders

No items found

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016